Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) FCF Margin (2017 - 2025)

Historic FCF Margin for Vistagen Therapeutics (VTGN) over the last 11 years, with Q4 2025 value amounting to 5827.39%.

  • Vistagen Therapeutics' FCF Margin fell 14342300.0% to 5827.39% in Q4 2025 from the same period last year, while for Dec 2025 it was 7639.11%, marking a year-over-year decrease of 17564100.0%. This contributed to the annual value of 8662.55% for FY2025, which is 62337900.0% down from last year.
  • Per Vistagen Therapeutics' latest filing, its FCF Margin stood at 5827.39% for Q4 2025, which was down 14342300.0% from 5356.2% recorded in Q3 2025.
  • Over the past 5 years, Vistagen Therapeutics' FCF Margin peaked at 66413.33% during Q1 2025, and registered a low of 39456.92% during Q1 2022.
  • For the 5-year period, Vistagen Therapeutics' FCF Margin averaged around 2755.73%, with its median value being 4469.76% (2023).
  • In the last 5 years, Vistagen Therapeutics' FCF Margin tumbled by -382561500bps in 2022 and then soared by 706706500bps in 2025.
  • Vistagen Therapeutics' FCF Margin (Quarter) stood at 3364.64% in 2021, then tumbled by -61bps to 5407.67% in 2022, then surged by 78bps to 1162.77% in 2023, then crashed by -278bps to 4393.16% in 2024, then plummeted by -33bps to 5827.39% in 2025.
  • Its FCF Margin was 5827.39% in Q4 2025, compared to 5356.2% in Q3 2025 and 7750.41% in Q2 2025.